ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · Real-Time Price · USD
1.630
+0.230 (16.43%)
At close: Nov 4, 2024, 4:00 PM
1.580
-0.050 (-3.07%)
Pre-market: Nov 5, 2024, 5:23 AM EST
Company Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.
| Country | Canada |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | David Parkinson |
Contact Details
Address: 999 West Broadway, Suite 720 Vancouver, BC V5Z 1K5 Canada | |
| Phone | 778 331 0962 |
| Website | essapharma.com |
Stock Details
| Ticker Symbol | EPIX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001633932 |
| CUSIP Number | 29668H708 |
| ISIN Number | CA29668H7085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ross Parkinson M.D. | President, Chief Executive Officer and Director |
| David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer |
| Peter A. Virsik M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer and Executive Vice President |
| Chandtip Chandhasin | Executive |
| Erica Osbourne | Executive |
| Erin Rudsinski | Executive |
| Loleta Harris | Executive |
| Neil Thapar | Executive |
| Nkengyal Barber | Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 8-K | Current Report |
| Sep 3, 2024 | 144 | Filing |
| Aug 5, 2024 | 8-K | Current Report |
| Aug 5, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 5, 2024 | 144 | Filing |
| Mar 7, 2024 | 8-K | Current Report |